Update on bicuspid aortic valve aortopathy
Standard
Update on bicuspid aortic valve aortopathy. / Girdauskas, Evaldas; Petersen, Johannes.
in: CURR OPIN CARDIOL, Jahrgang 32, Nr. 6, 11.2017, S. 651-654.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update on bicuspid aortic valve aortopathy
AU - Girdauskas, Evaldas
AU - Petersen, Johannes
PY - 2017/11
Y1 - 2017/11
N2 - PURPOSE OF REVIEW: The appropriate treatment of bicuspid aortic valve (BAV)-associated aortopathy is still controversial. We aimed to summarize recent evidence from the literature that focused on the prediction of aortopathy progression and adverse aortic events.RECENT FINDINGS: Following the detailed description of valvulo-aortic phenotypes in BAV disease in the previous imaging studies, the most current research focused on the definition of hemodynamic markers that may affect the progression of BAV-associated aortopathy and search for blood-born biomarkers to improve the prediction of adverse aortic events. Furthermore, genetic analyses are ongoing and some preliminary data will be presented.SUMMARY: Serological biomarkers are a novel and promising diagnostic tool for screening thoracic aortic aneurysmal disease and prediction future adverse aortic events. In combination with rheological imaging as well as traditional risk factors diagnostic accuracy and cost-effectiveness of care in BAV-associated aortopathy will improve significantly. VIDEO ABSTRACT: http://links.lww.com/HCO/A44.
AB - PURPOSE OF REVIEW: The appropriate treatment of bicuspid aortic valve (BAV)-associated aortopathy is still controversial. We aimed to summarize recent evidence from the literature that focused on the prediction of aortopathy progression and adverse aortic events.RECENT FINDINGS: Following the detailed description of valvulo-aortic phenotypes in BAV disease in the previous imaging studies, the most current research focused on the definition of hemodynamic markers that may affect the progression of BAV-associated aortopathy and search for blood-born biomarkers to improve the prediction of adverse aortic events. Furthermore, genetic analyses are ongoing and some preliminary data will be presented.SUMMARY: Serological biomarkers are a novel and promising diagnostic tool for screening thoracic aortic aneurysmal disease and prediction future adverse aortic events. In combination with rheological imaging as well as traditional risk factors diagnostic accuracy and cost-effectiveness of care in BAV-associated aortopathy will improve significantly. VIDEO ABSTRACT: http://links.lww.com/HCO/A44.
KW - Aortic Diseases/blood
KW - Aortic Valve/abnormalities
KW - Bicuspid Aortic Valve Disease
KW - Biomarkers/blood
KW - Heart Valve Diseases/complications
KW - Humans
U2 - 10.1097/HCO.0000000000000456
DO - 10.1097/HCO.0000000000000456
M3 - SCORING: Review article
C2 - 28795978
VL - 32
SP - 651
EP - 654
JO - CURR OPIN CARDIOL
JF - CURR OPIN CARDIOL
SN - 0268-4705
IS - 6
ER -